ABBV•benzinga•
U.S. FDA Approves AbbVie's RINVOQ® (upadacitinib) for Ankylosing Spondylitis (AS)
Summary
The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE: ABBV) RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) .
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 29, 2022 by benzinga